Catalent (NYSE:CTLT) received a $44.00 target price from investment analysts at Royal Bank of Canada in a research report issued on Wednesday. The brokerage currently has a “buy” rating on the stock. Royal Bank of Canada’s price objective would suggest a potential upside of 15.73% from the stock’s current price.
A number of other analysts have also recently weighed in on the company. UBS Group started coverage on Catalent in a research report on Tuesday, October 9th. They issued a “neutral” rating and a $48.00 price target for the company. JPMorgan Chase & Co. boosted their price target on Catalent from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 29th. Zacks Investment Research cut Catalent from a “buy” rating to a “hold” rating in a research report on Thursday, July 26th. ValuEngine cut Catalent from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, First Analysis raised Catalent from a “neutral” rating to an “outperform” rating and cut their price objective for the stock from $47.00 to $43.00 in a research report on Wednesday. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $48.30.
Shares of NYSE:CTLT traded up $1.91 on Wednesday, reaching $38.02. The company had a trading volume of 865,737 shares, compared to its average volume of 636,265. Catalent has a twelve month low of $34.24 and a twelve month high of $47.87. The stock has a market capitalization of $6.11 billion, a P/E ratio of 23.91, a P/E/G ratio of 2.50 and a beta of 1.45. The company has a debt-to-equity ratio of 2.44, a current ratio of 2.15 and a quick ratio of 1.79.
In other Catalent news, Director Donald E. Morel, Jr. acquired 10,000 shares of the business’s stock in a transaction that occurred on Thursday, September 13th. The stock was acquired at an average price of $43.00 per share, with a total value of $430,000.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Lance Miyamoto sold 6,525 shares of the business’s stock in a transaction dated Tuesday, October 16th. The stock was sold at an average price of $42.50, for a total value of $277,312.50. The disclosure for this sale can be found here. Insiders have sold a total of 184,335 shares of company stock valued at $8,161,727 in the last three months. 1.40% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of CTLT. Nelson Van Denburg & Campbell Wealth Management Group LLC bought a new position in Catalent during the second quarter valued at about $145,000. Moneta Group Investment Advisors LLC increased its stake in Catalent by 105.0% during the second quarter. Moneta Group Investment Advisors LLC now owns 3,515 shares of the company’s stock valued at $147,000 after acquiring an additional 1,800 shares during the period. CIBC Asset Management Inc bought a new position in Catalent during the third quarter valued at about $217,000. Hartford Investment Management Co. bought a new position in Catalent during the second quarter valued at about $220,000. Finally, Rehmann Capital Advisory Group increased its stake in Catalent by 1,895.9% during the second quarter. Rehmann Capital Advisory Group now owns 5,309 shares of the company’s stock valued at $222,000 after acquiring an additional 5,043 shares during the period. Hedge funds and other institutional investors own 92.08% of the company’s stock.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Read More: What are the benefits of a balanced fund?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.